Basel/Monaco, 22 April 2016: At the International Osteology Symposium in Monaco today, Straumann announced that it has extended the lifetime guarantee on all its Roxolid implants to include a monetary contribution to the follow-up treatment costs in the case of implant fracture, in some countries. The average amount is CHF 1000, but varies in different countries depending on local dental charges. Until now, the treatment costs for replacing an implant in the event of breakage had to be carried by the dentist and/or the patient. Straumann is the first leading dental implant manufacturer to offer a lifetime warranty covering the product and a contribution to the treatment costs. Because Roxolid is stronger than pure titanium2 and has excellent osseointegration capabilities, implant fractures are very rare and success rates are very high3. This is supported by extensive data from mechanical strength and durability tests and clinical trials. Publications from the initial clinical research program cover 922 implants, 607 patients and 57 clinical centers4 with up to 3-years’ follow-up3. One of the most recent publications, a scientific review, reported survival and success rates of 98.4% and 97.8%.3 Another recent publication reported 5-year results from a randomized controlled clinical trial showing that survival and success of Roxolid implants are maintained over time1. To add to this body of scientific evidence, Straumann’s Quality Compliance statistics show that the cumulated fracture rate of all 3.3mm Roxolid implants sold to date is just 0.04%2, which is significantly lower than the Straumann titanium equivalents. First launched in 2009, Roxolid is available on Straumann’s entire implant portfolio around the world, depending on registration processes. Some major markets have – for the most part – switched from titanium to Roxolid. The standard guarantee on all Straumann implants applies for the lifetime of the patient and covers the implant in case of breakage – irrespective of whether it is made of titanium, ceramic or Roxolid. The Lifetime Plus guarantee is available for Roxolid only, in Europe and North America, with other regions to follow depending on legal and organizational constraints. The Straumann Lifetime and Lifetime Plus guarantees are not valid if the instructions, recommendations and indications for product use are not observed. For further details please consult the Straumann Guarantee Terms and Conditions available from the local Straumann subsidiary. 1 Müller F, et al. Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: 5y results from a double-blind, randomized controlled trial. BMC Oral Health. 2015 Oct 12;15(1) 2 Data on file 3 Altuna P, et al. Clinical evidence on titanium–zirconium dental implants: a systematic review andmeta-analysis, Int J Oral Maxillofac Surg (2016), http://dx.doi.org/10.1016/j.ijom.2016.01.004 4 http://www.straumann.com/science-roxolid.html About Straumann Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 3500 people worldwide and its products and services are available in more than 100 countries through its broad network of distribution subsidiaries and partners. | 
Sweden – English
